Day: March 22, 2021

AzurRx BioPharma Announces Completion of Enrollment in Phase 2 Clinical Trial of MS1819 in Combination with PERT in the Treatment of Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency

Tauriga Sciences, Inc. Converts its U.S. Provisional Patent Application (Filed on March 17, 2020) to a U.S. Non-Provisional Patent Application

To Enhance Its Existing Intellectual Property Portfolio, the Company Filed an Additional U.S. Provisional Patent Application Directed to: Alternative Pharmaceutical...

error: Content is protected !!